Mink Current Deferred Revenue from 2010 to 2024
| INKT Stock | USD 0.68 0.01 1.45% |
Current Deferred Revenue | First Reported 2010-12-31 | Previous Quarter 171.9 K | Current Value 152.8 K | Quarterly Volatility 10.7 K |
Check Mink Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Mink Therapeutics' main balance sheet or income statement drivers, such as Net Interest Income of 584.4 K, Depreciation And Amortization of 118.7 K or Interest Expense of 216.6 K, as well as many indicators such as Price To Sales Ratio of 0.0355, Dividend Yield of 0.0 or Days Sales Outstanding of 0.0. Mink financial statements analysis is a perfect complement when working with Mink Therapeutics Valuation or Volatility modules.
Mink | Current Deferred Revenue |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Mink Stock Analysis
When running Mink Therapeutics' price analysis, check to measure Mink Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Mink Therapeutics is operating at the current time. Most of Mink Therapeutics' value examination focuses on studying past and present price action to predict the probability of Mink Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Mink Therapeutics' price. Additionally, you may evaluate how the addition of Mink Therapeutics to your portfolios can decrease your overall portfolio volatility.